Skip to main content
Immunotech Biopharm Ltd logo

Immunotech Biopharm Ltd — Investor Relations & Filings

Ticker · 6978 ISIN · KYG4721A1004 HKEX Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6978

About Immunotech Biopharm Ltd

http://www.eaal.net

Immunotech Biopharm Ltd is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of cellular immunotherapy products. The company focuses primarily on T cell immunotherapy, applying principles of immunology, cell biology, and genetics combined with advanced technology to develop treatments for malignant tumors and other major diseases. Founded in 2006, it is recognized as a pioneer in the domestic development of cellular immunotherapy products. It maintains a commitment to building systematic R&D platforms and GMP-compliant manufacturing facilities for individualized cell products.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2026
Regulatory Filings Classification · 100% confidence The document is a monthly return filed with the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Immunotech Biopharm Ltd for the month ended 30 April 2026. It details movements in authorized share capital, issued shares, treasury shares, share options, convertibles, and confirms compliance with listing rules. The document is a regulatory submission reporting share capital and shareholding movements, not a financial report, earnings release, or management discussion. It is not an announcement of a report but a regulatory filing itself. Therefore, it fits best under the category of Regulatory Filings (RNS).
2026-05-06 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 30 APRIL 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the poll results of the Annual General Meeting (AGM) held on 30 April 2026 for Immunotech Biopharm Ltd. It details the voting outcomes on various resolutions including adoption of audited financial statements, re-election of directors, appointment of auditors, and granting of mandates. The document does not contain the full annual report or financial statements but reports the results of shareholder voting at the AGM. It references the AGM Notice and Circular but does not include the reports themselves. The document length is 6517 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-04-30 English
EXCHANGE NOTICE - RESUMPTION OF TRADING
Regulatory Filings Classification · 90% confidence The document is an Exchange Notice from the Hong Kong Stock Exchange announcing the resumption of trading of a listed company’s shares. It is not a financial report, management announcement, or a delisting notice. It is a general regulatory announcement and falls under the fallback category for miscellaneous filings that do not fit other specific categories: Regulatory Filings (RNS).
2026-04-29 English
(1) INSIDE INFORMATION UPDATE ON CONDITIONAL NEW DRUG APPLICATION FOR EAL FOR THE PREVENTION OF POSTOPERATIVE RECURRENCE OF LIVER CANCER (2) RESUMPTION OF TRADING
Regulatory Filings Classification · 92% confidence The document is a formal stock exchange announcement under Hong Kong Listing Rule 13.09 and Inside Information Provisions, providing an operational update on a drug application and resumption of trading. It is not an annual, interim, earnings report, nor a detailed management discussion, financing update, M&A, or other specific category. It is an announcements-style regulatory filing, so it falls into the general Regulatory Filings category (RNS).
2026-04-28 English
TRADING HALT
Regulatory Filings Classification · 87% confidence The document is a brief announcement by Immunotech Biopharm Ltd published on the Hong Kong Exchange website stating that trading in the company’s shares has been halted pending an inside information announcement. It does not contain financial results, AGM materials, management changes, dividends, or other specific categories. It is therefore a generic regulatory announcement (fallback category).
2026-04-28 English
EXCHANGE NOTICE - TRADING HALT
Regulatory Filings Classification · 90% confidence The document is an HKEX Exchange Notice announcing a trading halt for a listed company’s shares. This is a regulatory announcement rather than a financial report, presentation or detailed filing type. It does not match any specific category like dividend, capital change, or management report, so it falls under the general “Regulatory Filings” category.
2026-04-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.